Intrexon, ZIOPHARM and MD Anderson in Exclusive CAR T Pact

Intrexon Corporation, a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news